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FUNCTIONAL SIGNIFICANCE OF THE INTERACTION BETWEEN INDUCIBLE 
COSTIMULATOR (ICOS) AND ITS LIGAND (ICOSL) 
ELIZABETH KIERAS 
ABSTRACT 
Background 
Inducible costimulator (ICOS) and its ligand (ICOSL) are a pair of costimulatory 
molecules that co-localize in germinal centers (GC).  This interaction is critical for 
the maturation of GC B cells to affinity-matured memory B cells and long-lived 
plasma cells.  Both ICOS and ICOSL are implicated in systemic lupus 
erythematosus (SLE). It is known that ICOSL sheds from the cell membrane and 
that the soluble form of ICOSL (sICOSL) is elevated in SLE; though the function 
of sICOSL is poorly understood.   While it is known that binding of ICOSL on 
antigen-presenting cells (APC) to ICOS on T cells leads to cell signaling resulting 
in T cell activation and differentiation, there is also some preliminary evidence 
that reverse signaling may also occur through ICOSL in APCs.   The binding 
interaction between ICOS and sICOSL has not been fully characterized and is 
important to understand if either molecule is to be targeted therapeutically.  The 
hypothesis evaluated in this study was that the ICOS: ICOSL interaction is a 
potent and critical mediator of proinflammatory signaling and immune activation 
that functions both via activated T cell-mediated forward signaling and APC-
mediated reverse signaling mechanisms and that ectodomain shedding of ICOSL 
is a protective mechanism that leads to down-regulation of the proinflammatory 
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signaling cascade initiated by this interaction.  The aim of this thesis is to 
characterize the binding interaction between ICOS and ICOSL and to provide a 
review of the literature and discuss future work that would enhance the biological 
understanding of this interaction and its role in lupus and other autoimmune 
diseases.   
Methods 
The binding interaction between ICOS and ICOSL was characterized using both 
soluble proteins and cells with expressed recombinant proteins.  Purified soluble 
ICOSL (sICOSL) was characterized using size-exclusion chromatography 
multiangle light scattering (SEC-MALS).  Surface plasmon resonance (SPR) was 
used to measure the binding affinity between sICOSL and human ICOS fused to 
the fragment crystallizable (Fc) portion of an immunoglobulin molecule 
(hICOS.Fc).   The binding interaction was further characterized to account for 
avidity between hICOS.Fc and sICOSL and between hICOS.Fc and ICOSL 
expressed recombinant on the cell surface using a solution-based binding 
method. 
Results 
Expressed recombinant and purified sICOSL dimerized over time and with 
increasing temperatures. The sICOSL: hICOS.Fc interaction did not follow a 
typical 1:1 binding interaction.  In-solution binding experiments resulted in a 
tighter equilibrium dissociation binding constant (KD) than the surface-based 
results obtained by SPR.  The KD for hICOS.Fc binding to human ICOSL 
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(hICOSL) expressed on cells agreed well with the KD for hICOS.Fc to the soluble 
protein, indicating that the in-solution binding measurement may measure 
binding avidity rather than affinity and that this may be the more physiologically 
relevant interaction.   
Conclusions 
I show in the experimental part of this study that the interaction between ICOS 
and ICOSL is quite potent and that much of the binding strength is due to avidity, 
or the combined strength of multiple parts of the molecules interacting with one 
another, rather than the affinity alone.  As this interaction is implicated in SLE 
pathogenesis, it would be useful to develop a clearer understanding of the most 
relevant physiological form of these molecules (soluble or transmembrane)  and 
of the biological signaling events that are initiated via this interaction in order to 
determine whether targeting ICOS or ICOSL may be therapeutically viable 
approaches. 
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INTRODUCTION 
 
Costimulation via CD28- and B7-family members 
The interaction between inducible costimulator (ICOS) and its ligand 
(ICOSL) is part of a costimulatory event that is required for T cell activation and 
differentiation to occur.  ICOS is a member of the CD28 family of costimulatory 
receptors expressed on T cells.  ICOSL is a member of the B7 family of ligands 
expressed on antigen presenting cells (APC).   
Costimulatory signaling is one of three signals that are required for T cell 
activation.  Signal 1 is the presentation of antigen peptide via major 
histocompatibility complex (MHC) on the surface of an APC to the T cell receptor 
(TCR) on a naive CD4+ or CD8+ T cell.  Signal 2 is the interaction between 
surface-bound costimulatory molecules on APCs with their receptors on T cells.  
Signal 3 is mediated by soluble cytokines which control differentiation into 
different effector T cells.  In the absence of the second costimulatory signal, the T 
cell enters an anergic state or undergoes apoptosis (Murphy et al. 2008: 324-
325).  Anergy is a tolerance mechanism in which the lymphocyte is 
hyporesponsive and functionally inactivated following an antigen encounter, but 
remains alive for an extended period of time (Schwartz, 2003).  Apoptosis, also 
known as programmed cell death, includes characteristic cellular changes 
including blebbing, shrinking, and fragmentation of the nucleus and chromosomal 
DNA (Elmore, 2007). 
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Figure 1:  Signals Required for T Cell Activation.  A. Antigen-presenting cells 
deliver three kinds of signals to naïve T cells.  Signal 1 is the presentation of 
antigen peptide via the MHC to the TCR.  Signal 2 is the binding of costimulatory 
ligands on APCs to costimulatory receptors on T cells.  Signal 3 is mediated by 
soluble cytokines which lead to differentiation of activated T cells into effector T 
cells.  B. In the absence of Signal 1, Signal 2 does not lead to T cell activation or 
differentiation.  C. Signal 1 in the absence of Signal 2 leads to T cell inactivation, 
or anergy.  (Murphy et al. 2008, Figures 8.19 and 8.23). 
 
The classic costimulatory event is B7-1 or B7-2 binding to Cluster of 
Differentiation 28 (CD28) on T cells.  This leads to naive T cell activation and 
increased interleukin-2 (IL-2) production primarily due to messenger ribonucleic 
acid (mRNA) transcription and stabilization.  IL-2 further activates T cells through 
binding to the IL-2 receptor (IL-2R), leading to increased T cell proliferation 
(Murphy et al. 2008: 345-346). In addition to the activating costimulatory 
receptor, CD28, activated T cells also constitutively express cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4), a CD28 family member, which also 
binds to B7-1 and B7-2, but with a higher affinity than CD28 (van der Merwe, 
1997).  Engagement of B7-1 or B7-2 with CTLA-4 initiates inhibitory signals to T 
A 
B C 
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cells, limiting further activation via CD28 (Chambers, 2001).  Thus, CTLA-4 has 
an important role in down-regulating inflammation.  CD28 is constitutively 
expressed on resting T cells and B7-2 is induced rapidly following antigen 
presentation to APCs, whereas expression of B7-1 and CTLA-4 is delayed for 
approximately 24 to 48 hours into the immune response (Collins et al., 2002).  
Thus the B7-2: CD28 interaction is likely the primary costimulatory interaction 
used to activate T cells following antigen presentation and the higher affinity B7-
1: CTLA-4 interaction is likely a negative feedback mechanism to inhibit immune 
over-proliferation that would occur due to unchecked CD28 signaling.  As 
evidence of its negative feedback role, CTLA-4 deficient mice die within several 
weeks of birth due to massive lymphoproliferation, infiltration, and multi-organ 
destruction (Waterhouse et al., 1995).  In keeping with the beneficial inhibitory 
effects of CTLA-4, the drug abatacept (CTLA-4-Ig, ORENCIA) has been 
approved for the autoimmune disease rheumatoid arthritis (RA) and for 
transplant rejection where inhibiting an overactive immune response is critical to 
managing disease (Gizinski et al., 2010).  
 
ICOS: ICOSL Interaction 
ICOS was first identified in 1999 as the third member of the CD28 
costimulatory family (Hutloff et al., 1999).  ICOS shares 24% sequence identity 
with CD28 and 17% identity with CTLA-4.  ICOS is a disulfide-linked homodimer, 
expressed on the surface of TH1, TH2, TH17, TFH, and TREG activated CD4
+ and 
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CD8+ T cells (Hutloff et al., 1999; Simpson et al., 2010).  Unlike CD28 and CTLA-
4, a single ligand has been identified for ICOS: the B7 family member ICOSL, 
also known as ligand of ICOS (LICOS), B7h, B7RP-1, B7-H2, and GL50 (Ling et 
al., 2000).  ICOSL is expressed on B cells, dendritic cells (DC), macrophages, 
and multiple non-lymphoid tissues, including tumor necrosis factor alpha (TNF-
)-activated fibroblasts, intraepithelial lymphocytes, brain tissue, lymph node and 
thymic tissue, lung, heart, kidney, liver, peritoneum, and testes (Aicher et al., 
2000;  Ling et al., 2000; Chambers, 2001). 
ICOSL binds to ICOS via multiple residues within its variable 
immunoglobulin (IgV) domain. In particular, the FDPPPF1 amino acid motif in the 
IgV domain is critical for forming contacts with ICOSL.  This motif is homologous 
to the MYPPPY1 motif on CD28 and CTLA-4, which binds B7-1 and B7-2.  The 
constant immunoglobulin (IgC) domain in ICOS has been shown to be critical for 
maintaining the structural integrity of the molecule and preventing nonspecific 
aggregates from forming (Chattopadhyay et al., 2006).  Signaling through ICOS 
in T cells has been fairly well characterized.  Like CD28, ICOS stimulation 
following ICOSL ligation sends an activating signal to T cells.  This leads to 
further T cell activation and differentiation and regulates cytokine and Ig 
production.  ICOS signaling plays a critical role in B cell differentiation, Ig class 
switching, germinal center formation, memory B cell development, and 
production of autoimmune antibodies by self-reactive B cells (Greenwald et al., 
                                                        
1 1-Letter amino acid abbreviations can be found in Appendix. 
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2005; McAdam et al., 2001).  Also like CD28, the intracellular domain of ICOS 
associates with the p85 subunit of phosphoinositide 3-kinase (PI3K) via the 
YMFM1 motif in the intracellular tail.  This is similar to the YMNM1 motif in CD28.  
The change in this motif, however, abolishes binding to growth factor receptor-
bound protein 2 (Grb-2), in which case the asparagine (N) residue in the YMNM1 
motif of CD28 appears to be critical for Grb-2 binding (Coyle et al., 2000).  
A major difference between ICOS and CD28 signaling is that ICOS does 
not induce IL-2 production but does induce high levels of IL-10 production, 
leading to TREG regulation, T cell tolerance, and autoimmunity (Greenwald et al., 
2005).  Additionally, ICOS is important for the induction of interferon gamma 
(IFN-γ), TNF-, IL-4, IL-5, IL-13, and IL-21 (Simpson et al., 2010).  ICOS 
costimulation appears to be critical at late stages in the immune response, 
suggesting that its inhibition may provide therapeutic benefit in treating diseases 
in which activated T cells are believed to contribute to disease progression 
(Coyle et al., 2000).   
Within secondary lymphoid organs, lymphocytes segregate into discrete B 
and T cell zones, or follicles.  Antigen activation increases the expression of C-C 
chemokine receptor type 7 (CCR7) on B cells, which causes migration to the 
follicular interface.  ICOS on TFH cells interacts with ICOSL on B cells within 
germinal centers to produce memory B cells and plasma cells, important 
components of adaptive immunity.  TFH cells are characterized by high 
                                                        
1 1-Letter amino acid abbreviations can be found in Appendix. 
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expression of C-X-C chemokine receptor type 5 (CXCR5), programmed cell 
death protein 1 (PD-1), and IL-21.  ICOSL and CD40 ligand (CD40L) have both 
been identified as required for TFH cells and for germinal center formation. 
ICOSL knockout mice are viable and do not display any obvious physical 
or behavioral abnormalities.  Homozygous knockouts show impaired T and B cell 
dependent immunological responses.  In particular, these mice produce fewer 
and smaller germinal centers upon antigen challenge and display lower 
immunoglobulin E (IgE) levels than wild-type mice in a murine asthma model.  T 
cells from these mice produce less IL-4 and IL-10 than wild-type animals and B-
cell isotype switching is also impaired (B6.129P2-Icosltm1Mak/J, 2014). 
 
Role of ICOS and ICOSL in SLE 
 Systemic lupus erythematosus (SLE) is a chronic inflammatory disease 
affecting the skin, joints, kidneys, lungs, and nervous system.  It is a 
heterogeneous autoimmune disorder, in which different patients exhibit different 
symptoms and disease severity (Systemic Lupus Erythematosus (Lupus), 2014).  
It is estimated that 1.5 million Americans and 5 million people worldwide suffer 
from lupus, with over 16,000 new cases reported annually in the United States 
(What is lupus?, 2014).  The average annual cost per lupus patient is $5,000 - 
$19,000 greater than the average annual medical cost for people without lupus 
and is much higher for patients who suffer from lupus nephritis (Assessing the 
Cost of Lupus, 2014). 
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Lupus is a chronic disease with periods of flares, or worsening symptoms, 
and remission.  It can range from mild to life-threatening.  Lupus treatment has 
improved considerably over the past several decades.  In the 1950s, most people 
diagnosed with SLE live less than 5 years, whereas today over 90% survive for 
more than 10 years, and 80-90% of SLE patients live a normal lifespan.  In late 
stages of disease, mortality risk if five-fold higher than the normal population and 
is attributed mainly to heart disease from atherosclerosis, as well as increased 
risks of infections and cancer (Systemic lupus erythematosus, 2014).  Many with 
lupus can lead relatively normal lives if properly treated.  However, quality of life 
is often affected due to symptoms such as fatigue and joint pain, and 
unpredictable flare periods.  Not all patients respond to current treatments and 
symptoms often worsen over time leading to complications such as organ 
damage, atherosclerosis, and kidney disease (Systemic Lupus Erythematosus 
(Lupus), 2014).  While SLE is not one of the leading causes of death worldwide 
and mortality rates due to lupus are fairly low, it is a chronic disease that affects 
overall quality of life, and in many cases, treatments are still inadequate at 
controlling the disease. 
Most lupus patients have autoantibodies directed against antinuclear 
antigens, including double-stranded DNA (dsDNA).  Lupus has been called the 
great imitator as it is characterized by many different symptoms, none of which 
are specific to lupus alone.  These include fever and fatigue, arthritis, malar rash, 
sores in the mouth and nose, hair loss, seizures and mental disorders, blood 
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clots and stroke, miscarriage, blood or protein in urine, and low blood counts 
(Systemic Lupus Erythematosus (Lupus), 2014).  
 Despite advances in therapy for SLE, the management and control of 
disease activity remains challenging.  SLE treatment depends on a patient’s 
symptoms and disease severity.  There are several different available 
assessments to measure disease severity in lupus.  Among these, some of the 
most widespread are the Physician Global Assessment (PGA), the British Isles 
Lupus Assessment Group (BILAG), and the SLE Disease Activity Index 
(SLEDAI).  The PGA is a global assessment based on a visual analog scale from 
0-3 of relative change over the last 2 weeks, where mild flare scores 1 point, 
moderate flares score 2.0-2.5 points, and severe flares score a 3.  The BILAG 
index evaluates disease activity over the past month in 8 separate organ systems, 
comprising a total of 86 items to be scored with a maximum score of 81.  The 
SLEDAI measures disease activity over the past 10 days and includes 24 
weighted clinical and laboratory items with a score ranging from 0-105 (Luijten et 
al., 2012).   
Serologic diagnosis is based on positive results from antinuclear antibody 
(ANA) and anti-extractable nuclear antigen (ENA) tests as well as at least 4 out 
of 11 clinical symptoms (Systemic Lupus Erythematosus (Lupus), 2014).  
Treatments include analgesics such as non-steroidal anti-inflammatory drugs 
(NSAIDs) and opioids to relieve pain, disease-modifying antirheumatic drugs 
(DMARDs) such as hydroxychloroquine, corticosteroids, and cyclosporine to 
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suppress the immune response, and biologics such as intravenous 
immunoglobulins (IVIG) and the recently approved anti-B Lymphocyte 
Stimulatory (BLyS) inhibitor, Benlysta (Hahn, 2011). 
For reasons that are not well understood, lupus and most other 
autoimmune diseases are much more prevalent in women than in men.  In 
general, women are 2.7 times more likely than men to develop an autoimmune 
disease.  Women are 9 times more likely than men to develop SLE (Quintero et. 
al., 2012).  It is believed that increases in female hormones, such as estrogen, 
may trigger lupus flares, and that the increased number of X chromosomes in 
females vs. males may account for this discrepancy between the sexes.   
Onset in women is typically observed during reproductive ages and may 
be associated with rises in hormones such as estrogen, progesterone, and 
prolactin, which have been shown to elicit a TH2 immune response.  SLE 
symptoms often worsen during pregnancy.  It appears that autoimmunity is 
related to the genes expressed on the X chromosome.  For example, males with 
two X chromosomes (XXY males) are more likely to develop autoimmune 
disease than typical XY males.  Females who have only a single X chromosome 
(X0) are less likely to develop autoimmune disease than typical females with two 
X chromosomes (XX).  Females who do not show skewed X chromosome 
inactivation, meaning that one X chromosome is inactivated in many more cells 
than another, are also more prone to autoimmune disease.  This often occurs 
due to a mutation on one X chromosome or due to age (Quintero et al., 2012).   
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ICOS costimulation is implicated in the pathogenesis of SLE.   A family-
based association study identified single nucleotide polymorphisms (SNP) within 
the CD28-CTLA4-ICOS locus that were increased in SLE families compared to 
controls.  A 3’ flanking region of CTLA-4 extending into the ICOS promoter was 
confirmed to be important region for SLE association (Cunninghame Graham et 
al., 2006).  In addition, ICOS+ T cells are increased in patients with active SLE 
compared to patients with inactive SLE or healthy controls (Zhiping et al., 2005).  
Elevated levels of CD4+ICOS+Foxp3+ T cells in SLE patients correlated with 
increased plasma levels of IL-10 and transforming growth factor beta (TGF-), 
which are known to be up-regulated by ICOS signaling (Liu et al., 2011; 
Greenwald et al., 2005).  Increased soluble ICOSL (sICOSL) is observed in the 
plasma of active SLE patients vs. inactive SLE patients, RA patients, or healthy 
controls (Her et al., 2009).  Finally, the Sanroque mouse, which contains a 
mutation in Roquin, a gene that normally limits ICOS expression by degradation 
of Icos mRNA, is found to exhibit high autoantibody titers and pathology 
consistent with lupus (Yu et al., 2007).  Together, these results suggest that 
signaling through the ICOS: ICOSL interaction is implicated in autoimmune 
disease, and specifically SLE. 
The signaling initiated upon ICOS: ICOSL interaction is dependent on cell: 
cell contact between APCs that express ICOSL and T cells that express ICOS.  
This is thought to occur in the context of other adhesion and costimulation events  
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Figure 2.  Role of ICOS Signaling in Autoimmune Disease. (Heissmeyer et 
al., 2005, Figure 1). 
 
during immune activation.  APCs are activated by contact with pathogens present 
in complexes of the foreign peptide and MHC.  Activated APCs up-regulate the 
expression of B7 and ICOSL. These ligands in turn signal to T cells.  The 
costimulatory signal from B7 through CD28 on T cells up-regulates ICOS 
expression on T cells and leads to the differentiation of TFH cells.  ICOS-
expressing TFH cells produce IL-21 and help B cells to generate antigen-specific 
antibodies.  Roquin down-regulates ICOS expression in wild-type T cells.  In 
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san/san T cells from Sanroque mice, ICOS expression is not repressed, leading 
to unregulated autoantibody production by B cells (Heissmeyer et al., 2005).  
Without Roquin present to inhibit ICOS expression, a feed-forward loop can 
emerge, in which activated TFH cells provide constant stimulation to GC B cells, 
leading to increased B cell maturation and antibody production, which can in turn 
lead to the production of self-reactive autoantibodies, which are the primary 
pathogenic mechanism of SLE and other autoimmune diseases.  It is possible 
that Roquin is more highly expressed in males than in females, or that it is 
inhibited by estrogen expression and contributes to the increased prevalence of 
SLE in females vs. males. 
 
Reverse signaling identified for B7 family members 
In addition to their roles in T cell signaling, the related costimulation molecules 
CD28 and CTLA-4 have also been shown to initiate reverse signaling cascades 
through their ligands B7-1 and B7-2 in APCs.  CTLA-4 activates indoleamine 2,3-
dioxygenase (IDO) and increases tryptophan (Trp) catabolism in APCs, which 
leads to decreased T cell proliferation.  Through its interaction with B7, CTLA-4 
has been shown to induce transcription of Ifng in a nuclear factor kappa-light-
chain-enhancer of activated B cells (NFB)- and p38 mitogen-activated protein 
kinase (MAPK)-dependent manner.  Interferon-gamma (IFN-γ) then acts to 
induce expression of IDO, which is responsible for Trp catabolism (Grohmann et 
al., 2002).  This reverse signaling has been shown to be part of the mechanism 
  13 
 
Figure 3.  ICOSL splice variants.  A. Expression of splice variants by RT-PCR.  (Ling et al., 2001, Figure 4).               
B. Sequence alignment of human splice forms.  Domain predictions shown are based on modeling in Vector NTI 
software (Life Technologies). (Modified from Ling et al., 2001, Figure 2). 
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of action of abatacept (Kremer et al., 2006).  CD28 reverse signaling through B7-
1 and B7-2 on DCs induces p38 MAPK-dependent expression of IL-6 and IFN-γ 
(Orabona et al., 2004).   
There is some reason to believe that reverse signaling may also occur 
through the ICOS: ICOSL interaction.  There are two different splice variants of 
ICOSL.  The more prevalent splice variant, B7-H2, is ubiquitously expressed and 
was found in brain, heart, lung, kidney, liver, lung, pancreas, muscle, 
gastrointestinal tissue, sex organs, and immune tissues.  The second splice 
variant, GL50, is only expressed in immune tissues, including leukocytes, spleen, 
and lymph nodes (Figure 3A).  The two splice forms differ only by 10 amino acids 
in their C-terminal intracellular tails (Figure 3B), (Ling et al., 2001).  Tang et al. 
show that ICOS-Ig binding to ICOSL on immature mouse DCs enhances p38 
MAPK-dependent IL-6 expression and increases in surface expression of B7-1, 
B7-2, and CD83 on DCs following ICOS-Ig stimulation (Tang et al., 2009). 
 
Ectodomain Shedding 
Ectodomain shedding, the release of the extracellular domain of protein through 
limited proteolysis, is a regulatory mechanism for transmembrane proteins.  In 
the B7 family, ectodomain shedding is unique to ICOSL.  The mechanisms of 
ectodomain shedding are as diverse as the proteins that it regulates (Arribas and 
Borroto, 2002).  The TNF family, which also plays a role in costimulation, also 
undergoes ectodomain shedding.  These proteins are cytokines that are 
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synthesized as transmembrane proteins.  The receptor-binding domains of these 
proteins are released extracellularly via ectodomain shedding.  In the case of 
TNF-, the protein responsible for this cleavage event is TNF- converting 
enzyme (TACE), also known as ADAM17.  TACE is a membrane-bound 
disintegrin metalloproteinase.  It is inhibited by tissue inhibitor of 
metalloproteinase 3 (TIMP-3) and synthetic metalloproteinase inhibitors (Amour 
et al., 1998). 
  There is evidence for ICOSL shedding in mice and in humans, but the 
importance of shedding is not well understood.  In mouse models of immune 
activation, ICOSL is rapidly shed from B cells following ICOS binding or B cell 
receptor (BCR) engagement (Logue et al., 2006).  While mouse models are 
useful for developing an initial understanding of the human immune system, 
many cell types and pathways which are found in mouse are not replicated within 
humans.  Therefore, it is always important to replicate findings from mice within 
human cells and systems before claiming translational significance (Mestas and 
Hughes, 2004).  ICOSL down-regulation on human peripheral blood B cells is 
observed following co-culture with ICOS-transfected cells for 48 hours in vitro.  
Interestingly, other costimulatory ligands, CD40, B7-1, and B7-2, were not down-
regulated following ICOS stimulation, suggesting the ICOSL shedding is specific 
to this molecule, and possibly important for its regulation.  Peripheral blood CD4+ 
and CD8+ T cells from SLE patients had higher ICOS expression whereas CD19+ 
B cells had lower ICOSL expression compared to healthy controls (Hutloff et al., 
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2004).  It is not known whether these decreased ICOSL levels are due to 
ectodomain shedding, or another mechanism.  One hypothesis is that shedding 
may be protective, as shed ICOSL may diffuse away from the GC interface, 
leading to decreased signaling through ICOS: ICOSL.  This is consistent with the 
observation of decreased expression of surface ICOSL as soluble ICOSL levels 
increase (Her et al., 2009).  
 
Hypothesis 
There is some evidence that in addition to the well-established signaling 
that occurs in T cells via ICOSL binding to ICOS that reverse signaling also 
occurs in APCs.  Previous studies show that the ICOS: ICOSL interaction is 
important in germinal center formation and downstream antibody production.  
ICOSL sheds from the cell membrane and the function of this form is poorly 
understood.  sICOSL is present in the circulation and is at higher than normal 
levels in the plasma of SLE patients (Her et al., 2009).  The binding interaction 
between shed ICOSL and ICOS is unclear.  One study shows that a monomeric 
form of ICOSL binds ICOS.Fc with a 4 M binding affinity (Brodie et al., 2000). 
This study used a saturation binding technique that did not provide any 
information about the on or off rates of binding.  It’s also unclear if monomeric 
ICOSL is relevant to either the transmembrane or even the shed ICOSL form.   
Chattopadhyay et al. (2006) showed that recombinant ICOSL is primarily a dimer 
in solution and can form dimers and higher order oligomers on the membranes of 
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Human Embryonic Kidney 293 T cells (HEK293T cells).  The binding interaction 
between ICOS and its ligand are important to define for potential drug targeting 
for either of these molecules.  The hypothesis tested in this study was that the 
ICOS: ICOSL interaction is a potent and critical mediator of proinflammatory 
signaling and immune activation that functions both via activated T cell-mediated 
forward signaling and APC-mediated reverse signaling mechanisms and that 
ectodomain shedding of ICOSL is a protective mechanism that leads to down-
regulation of the proinflammatory signaling cascade initiated by this interaction.  
Understanding the contributions of ICOSL to immune activation and down-
regulation is important in order to develop inhibitors of this interaction. 
As the ICOS: ICOSL interaction is implicated in SLE pathogenesis, it 
would be useful to develop a clearer understanding of the most relevant 
physiological form of these molecules (soluble or transmembrane)  and of the 
biological signaling events that are initiated via this interaction in order to 
determine whether targeting ICOS or ICOSL may be therapeutically viable 
approaches.  In the experimental part of this study the binding affinity for the 
sICOSL: ICOS interaction was measured using surface plasmon resonance 
(SPR).  Purified expressed recombinant soluble ICOSL (sICOSL) was 
characterized using size-exclusion chromatography multiangle light scattering 
(SEC-MALS) in order to determine the oligomerization state(s) of the molecule, 
which helped to guide the interpretation of the binding data.  Based on these 
results, the binding interaction was further characterized to explore the effect of 
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avidity on this interaction using both sICOSL and ICOSL expressed recombinant 
on the cell surface using a solution-based binding method.  Additionally, relevant 
literature around reverse signaling and ectodomain shedding of ICOSL is 
reviewed and potential future directions for this research are explored, especially 
as they relate to development of therapeutics for SLE that target ICOS and 
ICOSL.  
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MATERIALS AND METHODS 
 
Reagents 
 Purified recombinant human ICOS fused to the Fc portion of an 
immunoglobulin molecule (hICOS.Fc) expressed recombinant and purified from 
NS0-derived murine myeloma cells was purchased from R&D Systems.  This 
molecule consists of the extracellular portion of ICOS (Glu21 – Phe141) fused to 
the hinge, CH2, CH3 domain of human IgG1 to form a disulfide-linked homodimer 
with a monomeric molecular mass of 40.3 kilodalton (kDa) and 50-60 kDa by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under 
reducing conditions.  The lyophilized protein was reconstituted to 100 g/mL in 
sterile phosphate buffered saline (PBS).   
Purified, recombinant monomeric hICOSL FH6, or sICOSL, expressed in a 
Chinese hamster ovary (CHO) suspension cell line (Icosagen) was obtained from 
the protein expression and purification laboratory at Pfizer.  The final 
concentration was 2.67 mg/mL in calcium and magnesium free PBS (PBC-CMF), 
pH 7.2.  The material was 91% monomer and 9% higher molecular weight 
species, by size exclusion chromatography (SEC).  The molecular weight by non-
reduced SDS-PAGE was 40-66 kDa.  It was stable upon three freeze thaw 
cycles.   
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Cell Culture 
 hICOSL was expressed recombinant on the surface of CHO cells 
transfected with DRB1*1501/DRA0101 (DR2) chains (CHO DR2 cells) (Scholz et 
al., 1998).  CHO DR2 hICOSL cells and control CHO DR2 cells were cultured in 
media containing 50% Dulbecco’s Modified Eagle’s Medium (DME)/50% Ham’s 
F-12 medium without hypoxanthine, thymidine plus 10% fetal calf serum, 10 mM 
HEPES, 1% L-Glutamine, 0.22 mg/mL hygromycin B, 0.44 mg/mL G418 
(geneticin), and 16.4 g/mL gentamicin.  Cells which were stored in liquid 
nitrogen at a concentration of approximately 1 x 106 cells/mL in media with 10% 
DMSO.  Cells were thawed, and rinsed with media to remove the dimethyl 
sulfoxide (DMSO).  Cells were diluted 15x into a T75 flask (BD Biosciences).  
Flasks were placed in an incubator at 37oC, 5% carbon dioxide (CO2) and were 
allowed to grow approximately 3 to 4 days until they were confluent.  Every 3 to 4 
days, media was aspirated from T75 flasks and cells were harvested via 
treatment with 25 mM EDTA in PBS for approximately 5 minutes.  After about 5 
minutes, cells were dissociated from the wall of the flask via manual force and 
approximately 20 mL media was added back to the flask to dilute the EDTA to an 
ineffective concentration. Cells were split approximately 1:30 to 1:40, depending 
on the level of confluence and the amount of time predicted to elapse before next 
harvest into 8 to 10 T-225 flasks (BD Biosciences) in order to grow a sufficient 
number of cells for a single KinExA experiment.  On the day the experiment was 
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to be performed, cells were again harvested from all flasks using 25 mM EDTA 
and reconstituted at the maximum tolerable concentration, generally about 1 x 
107 cells/mL or slightly less.  Number of cells and viability were measured by 
diluting a small number of cells in trypan blue (Life Technologies) and counting 
using a hemocytometer and microscope. 
 
Surface Plasmon Resonance 
 Binding interactions were measured by surface plasmon resonance (SPR) 
using a Biacore 2000 instrument (GE Healthcare, Uppsala, Sweden).  All 
experiments were performed at 25oC.  Briefly, proteins were immobilized on  a 
carboxymethylated dextran 5 (CM5) sensor chip surface (GE Healthcare) using a 
mixture of 5.75 mg/mL N-hydroxysuccinimide (NHS) and 37.5 mg/mL N-ethyl-N’-
(30-dimethylaminopropyl) carbodiimide (EDC) to activate the surface followed by 
an anti-human IgG antibody  (GE Healthcare) diluted in 10 mM sodium acetate, 
pH 5 on three different flow cells.  The surface was subsequently blocked with 1 
M ethanolamine hydrochloride-NaOH, pH 8.5.  The fourth flow cell was left blank 
but was activated and blocked as described above.  These reagents were 
supplied by the instrument manufacturer (GE Healthcare). The instrument 
running buffer and sample buffer for the immobilization and subsequent binding 
analyses was PBS-NET (8.1 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.2, 287 mM 
NaCl, 2.7 mM KCl, 3.2 mM ethylenediaminetetraacetic acid (EDTA), 0.005% 
Tween 20).  After immobilization, hICOS.Fc (R&D Systems) was captured on the 
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antihuman IgG sensor chip surface at a concentration of 10 g/mL for 1 minute at 
a flow rate of 10 L/min. Average surface densities on the three surfaces ranged 
from 87 – 239 response units (RU).  After capture, various concentrations of 
sICOSL were each injected in triplicate at concentrations ranging from 31.25 – 
1,000 nM for 2 minutes at a flow rate of 30 L/min and were each allowed to 
dissociate for 5 min.  All surfaces were regenerated using one 30 s pulse of 3 M 
MgCl2 followed by a 30 s pulse of a detergent combination consisting of the 
following;  (0.3% (w/w) CHAPS, 0.3% (w/w) zwittergent 3-12, 0.3% (v/v) Tween 
80, 0.3% (v/v) Tween 20, 0.3% (v/v) Triton-X-100) at a flow rate of 50 L/min.  
Data was double-referenced in Scrubber v. 2.0b software (BioLogic Software) 
(Myszka, 1999).  The transformed data were fit to 1:1 Langmuir binding models 
using BiaEvaluation v. 4.1.1 (GE Healthcare) and to a 4 parameter logistic 
nonlinear regression model in Scrubber v. 2.0b (Biologic Software).  The 1:1 
kinetic binding model is based on the following equations, where A and B are 
individual analytes (sICOSL and hICOS.Fc) and AB is the bound product; ka is 
the association rate constant, or on-rate; kd is the dissociation rate constant, or 
off-rate; KD is the dissociation binding constant, or binding affinity:  
 and (Önell and Andersson, 2005).  The 4 
parameter logistic nonlinear regression model is as follows, where A is the 
minimum asymptote; B is the Hill slope, which refers to the steepness of the 
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curve; C is the inflection point of the curve; and D is the maximum asymptote:   
KD = ((A-D)/(1+((x/C) ^B))) + D (Motulsky 2007). 
 
Protein Characterization 
sICOSL sample was further characterized for stability by size-exclusion 
chromatography-multiangle light scattering (SEC-MALS) under various 
experimental conditions by analyzing four different samples which were treated 
under the following conditions:  freshly thawed, stored at 4oC for 24 hours, stored 
at room temperature for 24 hours, or stored at 37oC for 24 hours.  Samples were 
run at stock concentration, 2.67 mg/mL, in PBS-CMF.  Samples were analyzed 
by SEC using the 2695 separation module (Waters) followed by multi-angle light 
scattering (MALS) using the miniDAWN TriSTAR (Wyatt Technology).  SEC data 
was collected using Millennium software (Waters) and MALS data was collected 
using Astra V software (Wyatt Technology.  Data was analyzed using miniDAWN 
and Optilab rEX (Wyatt Technology).  Peaks were integrated in order to 
determine the relative percent of total mass recovered under each peak 
 
In solution binding experiments (KinExA) 
 A KinExA instrument from Sapidyne (Boise, ID) was used for binding 
experiments done in solution or on cells.  In this case, hICOS.Fc is the receptor 
and sICOSL is the ligand.    
 
  24 
Bead preparation: 
Three types of beads were coated with sICOSL to determine which 
offered the optimal signal for hICOS.Fc detection: polymethylmethacrylate 
(PMMA), azlactone, and sepharose.  For immobilization, 50 g of sICOSL 
prepared in 1 mL PBS, pH 7.4 was added to 200 mg PMMA beads (Sapidyne), 
and 20 g of sICOSL prepared in 1 mL 50 mM sodium carbonate, pH 9.6 
(coating buffer) was added to 50 mg dry azlactone beads (UltraLink, Pierce 
Biotechnology) or to 1 mL of NHS-activated sepharose™ beads (pre-rinsed 5x 
with cold water and once with coating buffer to remove isopropanol storage 
solution) and the mixtures were tumbled for 2 hours at room temperature.  Beads 
were centrifuged for approximately 30 s and then the supernatant containing 
coating solution was discarded and replaced with 1 mL of blocking buffer (10 
mg/mL bovine serum albumin (BSA) in PBS for PMMA beads or 10 mg/mL BSA 
in 1 M Tris, pH 8.6 for azlactone and sepharose beads).  Beads were tumbled in 
blocking buffer for approximately 1 hour at room temperature.  The immobilized 
and blocked beads were added to 27 mL of sample buffer (PBS + 1 mg/mL 
BSA). 
Signal Calibration: 
In order to measure the net fluorescent signal generated by the receptor, 
hICOS.Fc binding to sICOSL on each bead set, a solution of 100 pM hICOS.Fc 
in PBS + 1 mg/mL BSA (running buffer) was prepared.  Prior to beginning the 
automated run, each bead set was calibrated to determine a sufficient volume of 
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beads to fill the detection flow cell at a flow rate of 1 mL/min.  For each sample, a 
fresh set of beads was injected, followed by the hICOS.Fc sample, followed by 1 
g/mL secondary antibody, followed by backflush of the beads and wash steps 
with running buffer.  Net signal was calculated using the following equation: 
([(Signal 100%) – (NSB)], where Signal 100% is the signal for the hICOS.Fc 
alone when no sICOSL is bound; and NSB refers to non-specific binding, or 
background binding fluorescence from the secondary labeled probe interacting 
with the beads or flow cell.  Subsequent signal tests were performed using 
sepharose beads following the method described above, but coating beads with 
increasing concentrations up to 50 g/mL sICOSL and at varying concentrations 
and volumes of hICOS.Fc.   
KD Measurement: 
 An experiment was performed to determine the approximate KD for the 
ICOS-ICOSL interaction and to determine the preferred hICOS.Fc concentration 
for a full KD experiment.  A 150 pM stock solution of hICOS.Fc was prepared.  
sICOSL was diluted serially from 500 nM 10-fold to 50 fM into 150 pM hICOS.Fc.  
Solutions were incubated for 7 hours at room temperature in order to reach 
equilibrium.  5 mL of running buffer or sample were injected at 250 L/min in 
each cycle followed by 1 g/mL secondary antibody.  All samples were run in 
duplicate.  KinExA Pro software was used to calculate the KD using a 4 
parameter non-parametric fit model (Figure 4) and best-fit analysis using lowest 
sum of squares. 
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Figure 4.  Equilibrium binding determination schematic via KinExA. 
(Modified from Sapidyne Instruments, Inc.) 
 
Based on the results of the above experiment, subsequent experiments 
were performed to more precisely determine the KD for the sICOSL: hICOS.Fc 
interaction.  For these experiments sepharose beads were coated with 50 g/mL  
sICOSL, as described above.  hICOS.Fc was kept constant at 50 pM, 150 pM, or 
500 pM in three independent experiments.  sICOSL was titrated using 2-fold 
dilutions at various concentrations ranging from 2.44 pM to 40 nM.  Solutions 
were incubated from 8 to 30 hours in order to allow each sample to come to 
equilibrium.   
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Within a single experiment, all samples were run in duplicate.  Data from 
individual experiments was fit using KinExA Pro software, v. 3.2.6 (Sapidyne).  
Data from multiple experiments was fit using n-Curve Analysis software, v. 3.2.6 
(Sapidyne) using the analysis method “Affinity, Standard”. 
Cell-based in-solution binding experiment: 
 A similar experiment was performed on KinExA using expressed 
recombinant hICOS.Fc and hICOSL expressed on CHO DR2 cells.  The overall 
method for measuring the interaction between hICOS.Fc and hICOSL on CHO 
DR2 cells was run in a similar manner as described above, replacing 
recombinant sICOSL with CHO DR2 cells that over-express hICOSL or control 
CHO DR2 cells that do not express ICOSL.  Starting cell concentrations ranged 
from 1.217 x 107 cells/mL diluted by 2- to 4-fold down to 5 cells/mL in hICOS.Fc 
was kept at a concentration of 100 pM or 2 nM.  Cells and hICOS.Fc were rocked 
for approximately 18 hours at room temperature.  Cell/hICOS.Fc mixture was 
placed in a centrifuge at 1,500 rpm (approximately 400xg) for 6 minutes to pellet 
the cells and any hICOS.Fc that was bound to the cells.  Supernatant containing 
media/buffer and free hICOS.Fc was aspirated away from pellet, filtered, and put 
into conical tubes to be run on KinExA. 
Sepharose beads were coated with 50 g/mL hICOSL, as described 
above and 0.5 g/mL secondary antibody was used to detect hICOS.Fc bound to 
the beads.  For each sample, a fresh set of beads was injected, followed by the 
cell/hICOS.Fc sample (in which only free hICOS.Fc remained after 
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centrifugation), followed by secondary antibody, followed by backflush of the 
beads and wash steps with running buffer.  Within each experiment, all samples 
were run in duplicate.  Data was fit using n-Curve Analysis software, v. 3.2.6 
(Sapidyne) using the analysis method “Affinity, Unknown Ligand”.  This analysis 
uses Avogadro’s number to convert the concentration of hICOSL from cells/mL to 
a molar unit in order to determine the KD of binding using the equation: 
Molecules/cell = (Molar equivalent of cell receptor * 6.02*10
23
)/(cells/mL*1,000) 
  
  29 
RESULTS 
 
Binding Affinity between sICOSL and hICOS.Fc 
Interactions between ligand and receptor costimulatory pairs are an 
important signal in the immune response. In the case of CD28 and its ligands, 
B7-1 and B7-2, the binding affinity is approximately 4 and 20 μM, respectively.  In 
contrast these same ligands bind the coinhibitory molecule, CTLA-4, with about 
10- to 20-fold stronger affinity.  As CD28 is constitutively expressed on resting T 
cells and B7-2 is rapidly expressed on APCs, it is believed that B7-1 and CTLA-4 
expression occurs after a delay of 24 to 48 hours.  Crystallographic studies 
indicate that B7-1 tends to dimerize, whereas B7-2 does not.  Additionally, CD28 
homodimers are monovalent, whereas CTLA-4 is bivalent, leading to an avidity-
enhanced interaction of B7-1 with CTLA-4, which has the ability to override the 
costimulatory interaction between B7-2 and CD28 (Collins et al., 2002), Thus the 
B7-1: CTLA-4 interaction likely overrides the costimulation driven by B7-2: CD28, 
attenuating an overactive immune response that left unchecked can lead to 
autoimmune diseases, such as SLE.  In order to more fully understand the effect 
of immune activation contributed by ICOS: ICOSL, I designed and performed 
experiments to understand how their binding properties compare to these other 
costimulatory molecules.   
My first aim was to characterize the binding interaction between ICOS and 
ICOSL.  There is no best technique to measure binding kinetics between two 
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membrane-associated proteins and this is an important feature of this interaction 
in GCs that go on to activate immune cells.  However, much can be learned by 
examining the binding energy of soluble forms of membrane-associated proteins 
to better understand the rates of these interactions.  Therefore, I used a soluble 
form of ICOS (hICOS.Fc) and both a soluble and cell-associated form of ICOSL 
(sICOSL and hICOSL) to understand the kinetics of this interaction.   
I first examined the soluble purified proteins using SPR in order to 
determine how the on and off rates contribute to the overall binding energy.  To 
avoid inactivation of hICOS.Fc via direct immobilization on the SPR surface, 
hICOS.Fc surface was prepared by capture onto antihuman IgG (Figure 5A).  
The sICOSL binding curves shown in black (Figure 5B) show an initial rapid 
association, illustrated by a steep rise in binding at all concentrations, followed by 
a slower association phase rise over the remainder of the injection time.  
Samples at the highest concentrations were at or close to equilibrium near the 
end of the 120 s injection time.  At the end of the injection, samples showed 
apparent 2-phase dissociation: an initial rapid decline, followed by a more 
gradual phase.  Most samples did not return to baseline over the 360 s 
dissociation period. 
This was unexpected because the shape of the binding curves did not 
match the shape expected of a 1:1 binding interaction.  In addition, the fit to the 
data (shown in red) did not fit well to this model (Figure 5B).  In fitting the data, I 
focused on the initial rapid dissociation phase, as the latter slow dissociation  
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Figure 5.  SPR Binding Experiments for hICOSL: hICOS.Fc Interaction.      
A. Preparation of the SPR surface to measure binding interaction.  B. sICOSL 
was injected over captured hICOS.Fc at 1,000, 500, 250, 125, 62.5 and 31.25 
nM. Data shown are 3 replicates with binding data in black and 1:1 fit in red.   
Residual plot shows distance between the fit data and raw data for a given time 
point for a given binding curve.  C. Equilibrium KD fit using 4 parameter logistical 
nonlinear regression model using binding data taken just before the end of the 
injection. 
 
phase may be at least partially explained by an artifact of the surface-based 
measurement, which is rebinding of dissociated sICOSL molecules to other 
hICOS.Fc molecules on the surface.  Mean values from intra-experimental 
triplicates acquired over three different binding surfaces (+/- the standard 
deviation) are 1.9 (+ 0.3) x 105 M-1s-1 for the ka (on-rate), 3.0 (+ 0.1) x 10
-2 s-1 for 
the kd (off-rate), and 160 (+ 20) nM for the KD (affinity).  The average normalized 
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Pearson’s chi-squared (χ2/Rmax) value, a measure of goodness of fit, from 3 
independent surfaces was 5.3%.  Additionally, the equilibrium KD was calculated, 
and is approximately 170 (+30) nM (Figure 5C).  As the kinetic fit does not truly  
reflect the raw data, the kinetic binding constants should not be considered as 
truly representative of this interaction.  The poorness of fit of the overall binding 
curve to a 1:1 interaction indicates that this binding system may not be 
measuring a true binding affinity for a 1:1 interaction, and that a more complex 
interaction might be occurring between these two molecules.  Further 
investigation of the oligomerization state of sICOSL is warranted based on this 
data to determine if the molecule used in this experiment is monomeric. 
 
Protein Characterization 
The poorness of fit to a 1:1 binding molecule was unexpected as sICOSL 
was expected to be monomeric and the SPR experiment was designed using low 
surface densities and with the bivalent hICOS.Fc on the surface in order to 
minimize rebinding effects.  There are several potential reasons that could 
explain this.  One plausible explanation is that one or both of the species 
involved in the interaction may not be a monomer.  As the form of ICOS used in 
these experiments contains two extracellular binding domains of the ICOS 
molecule fused to an Fc domain, and as the SPR experiment was designed to 
measure a 1:1 interaction by capturing hICOS.Fc on the surface and using  
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Figure 6. SEC-MALS characterization of sICOSL. 
 
sICOSL in solution, the sICOSL protein should be further characterized to 
determine if it is a monomer. 
Therefore, the purified recombinant sICOSL protein used for subsequent binding 
experiments was first characterized for the presence of dimeric vs. monomeric 
protein forms by SEC-MALS.  Results from these experiments revealed three 
different peaks that corresponded to molecular weights of approximately 70 kDa, 
40 kDa, and 45 kDa (Figure 6).  Initial characterization following purification 
revealed a non-reduced molecular weight by SDS-PAGE of 40-66 kDa, likely 
reflecting glycosylation as the theoretical molecular weight of the protein is 25.4 
kDa.  Therefore, the 40 and 45 kDa peaks observed by SEC- MALS are  
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Table 1. SEC-MALS characterization of sICOSL 
 Peak 1 Peak 2 Peak 3 
MW 
(kDa) 
% mass MW 
(kDa) 
% mass MW 
(kDa) 
% mass 
0 hr  77 6.3% 41 53.8% 48 39.9% 
4 C 24 hr 50 12.0% 39 49.0% 42 39.0% 
RT  24 hr 78 9.2% 41 50.5% 44 40.3% 
37 C  24 hr 71 28.3% 41 43.0% 47 28.7% 
 
consistent with monomer forms that have slightly different glycosylation, whereas 
the 70 kDa peak is consistent with the size of a dimeric form.  The percent mass 
recovery for the apparent dimeric 70 kDa peak varied from 6% in the freshly 
thawed sample to up to 28% in a sample that was incubated at 37oC for 24 
hours.  The sample that most closely matches the conditions used in subsequent 
experiments of this study was incubated at room temperature for 24 hours.  This 
showed 9% apparent 70 kDa dimeric species (Table 1). 
These results may partially explain the poorness of fit to the 1:1 model 
from the SPR experiments.  It appears that sICOSL has a propensity to form 
non-covalent dimers.  This is consistent with evidence that ICOSL dimerizes on 
cell membranes (Chattopadhyay et al., 2006).  ICOS is also known to form 
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homodimers on the membranes of T cells (Hutloff et al., 1999).  Therefore, it is 
possible that the 1:1 binding affinity is not the most physiologically relevant 
binding parameter for this interaction, and that an avidity measurement in 
solution or on cells may be a better indicator of the biological interaction between 
these two molecules. 
 
Measurement ICOS: ICOSL Binding Avidity 
As the SPR binding data did not fit a typical 1:1 binding interaction, a 
second orthogonal technique was used to measure the KD for the interaction 
between sICOSL and hICOS.Fc.  Characterization of sICOSL revealed that the 
protein has a propensity to form dimers in solution over time, although the 
sICOSL protein alone is still predominantly monomeric.  It is possible that when 
sICOSL is incubated with hICOS.Fc that this may increase the likelihood of dimer 
formation of sICOSL.  A SEC-MALS experiment was performed to try to 
determine the stoichiometries of binding between these two proteins (data not 
shown), but there were too many overlapping peaks and results were difficult to 
decipher.  The binding interaction between two dimers typically results in a higher 
functional affinity than the intrinsic affinity of two monomers as the dissociation of 
one domain does not necessarily coincide with the dissociation of the 
corresponding dimeric domain, resulting in an increased functional affinity, or 
avidity (Male et al. 2013: 57-58).  If neither the recombinant nor the physiological 
forms of ICOS and ICOSL exist as monomers, then a measurement of the 
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Table 2. KinExA Signal Test Results.  Results are from a single experiment run 
in duplicate.  Signal is mean +/- the standard deviation.  Net signal is signal for 
hICOS.Fc minus signal for blank. 
  Signal Net Signal 
Azlactone 
Blank 0.0445 (+ 0.009)   
100 pM hICOS.Fc 0.20 (+ 0.01) 0.16 
Sepharose 
Blank 0.129 (+ 0.001)   
100 pM hICOS.Fc 0.313 (+ 0.006) 0.184 
PMMA 
Blank 0.0133 (+ 0.0002)   
100 pM hICOS.Fc 0.124 (+ 0.004) 0.111 
 
binding avidity is more relevant than the binding affinity, and the avidity will likely 
be more potent than the 1:1 binding affinity.   
KinExA, short for kinetic exclusion assay, is a complementary technique to 
SPR that can be used to measure binding interactions between two unlabeled 
soluble binding partners or between a soluble protein and a cell-surface protein.   
The first set of experiments was designed to determine which bead set gave the 
highest fluorescent signal when coated with sICOSL.  Of the three bead sets that 
were tested, the sepharose beads gave the highest net signal when a solution of 
100 pM hICOS.Fc was injected (vs. background binding) (Table 2).  Further 
optimization of hICOSL coating concentration onto the beads and the volume of 
ICOS.Fc injected was performed in order to obtain a net signal within the linear 
detection range of 0.5 to 1.5 V (data not shown).  Beads were coated with a  
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Figure 7. sICOSL binding to hICOS.Fc by KinExA.  A  Initial titration 
experiment over broad concentration range to estimate KD for interaction and 
range of ligand concentrations required for KD determination.  B  Combined 
analysis of 3 independent experiments at 50, 150, and 500 pM hICOS.Fc 
respectively, and with sICOSL titrated 2-fold from 40 nM to 2.44 pM.  C  KD and 
95% CI from combined analysis of 3 experiments. 
 
higher concentration of hICOSL (50 g/mL) for all experiments that were 
performed for measurement of KD. 
hICOS.Fc was prepared at a 150 pM and hICOSL was titrated 10-fold 
from 500 nM to 50 fM, as described in Methods.  Equilibrated samples were run 
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in the KinExA system as described and detected via a Dylight649-conjugated 
antihuman secondary antibody (Jackson Immunoresearch).  Concentration vs.  
fluorescence values were plotted and the KD was estimated to be 183 pM with a 
95% confidence interval (CI) of 660 fM to 443 pM (Figure 7A).   
Based on the initial KD estimate, subsequent experiments were performed 
to more precisely determine the KD for the sICOSL: hICOS.Fc interaction.  
sICOSL was titrated using 2-fold dilutions over a narrower concentration range 
focused around the estimated KD.  Concentrations of hICOS.Fc were kept 
constant at either 50, 150, or 500 pM in three independent experiments.  In order 
to obtain an accurate KD measurement using KinExA, it is critical that the 
receptor concentration is close to or below the KD value.  When multiple curves 
are run at different receptor concentrations for the same interaction, curves may 
be analyzed together in order to obtain a more accurate determination of the KD.  
Concentration vs. fluorescence plots were generated for each independent 
experiment, as in Figure 7A.  Data from all three experiments was combined in 
order to obtain a more accurate determination of the KD for the binding system 
(Figure 7B).  The KD from this combined analysis is 190 pM with a 95% CI from 
65 to 394 pM (Figure 7C). 
As ICOSL is expressed on the cell surface of APCs, KinExA was also 
used to measure the binding interaction between hICOS.Fc and hICOSL 
expressed on CHO DR2 cells.  Cells were titrated from 1.217 x 107 cells/mL 2-
fold down to 5 cells/mL, as described in Methods, at 100 pM or 2 nM hICOS.Fc.   
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Figure 8.  Affinity Determination on hICOSL expressing CHO DR2 cells.  A  
Combined analysis of two curves prepared at the same time from the same batch 
of cells using two different concentrations of hICOS.Fc.  B  KD and 95% CI from 
whole cell analysis.  C  Expression level from whole cell analysis. 
 
To determine the KD of binding for hICOSL to hICOS.Fc, concentration vs. 
fluorescence curves were fit individually and then plotted together using the 
whole cell analysis to determine the expression level of hICOSL on the CHO 
DR2 cells and the KD (Figure 8A).  The KD from this analysis is 296 pM with a 
95% CI from 81 pM to 2 nM (Figure 8B).  The expression level is 2 x 1021 
molecules hICOSL/cell with a 95% CI from 7 x 1020 to 1 x 1021 molecules/cell 
(Figure 8C).  No binding was observed to the negative control CHO DR2 parental 
cell line that does not express hICOSL, as expected (data not shown).   
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The confidence intervals for the cell-based binding data are higher than 
ideal.  The primary source of variability in this data is likely due to the behavior of 
the cells during the overnight incubation with hICOS.Fc that is required in order 
for the binding system to reach equilibrium.  Visualization of cell viability using 
Trypan blue following the overnight incubation of cells with hICOS.Fc reveals that 
there is some cell death that occurs during the overnight incubation of hICOSL-
expressing CHO cells with hICOS.Fc.  However, the fact that the KD is so similar 
to the solution-based KD lends confidence to this data.   
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DISCUSSION 
 
The ICOS: ICOSL interaction is implicated in SLE pathogenesis; yet there 
are several aspects of the biology of this interaction that are poorly understood.  
Among these are the overall potency of the binding interaction of both the shed 
and transmembrane forms of ICOSL with ICOS on T cells, the function of shed 
ICOSL, and the biological effects of reverse signaling in humans.  Developing an 
improved understanding of the biology of this interaction is useful in order to 
determine whether targeting this interaction may be a viable therapeutic 
approach for the treatment of SLE.  The hypothesis evaluated in this study was 
that the ICOS: ICOSL interaction is a potent and critical mediator of 
proinflammatory signaling and immune activation that functions both via activated 
T cell-mediated forward signaling and APC-mediated reverse signaling 
mechanisms and that ectodomain shedding of ICOSL is a protective mechanism 
that leads to down-regulation of the proinflammatory signaling cascade initiated 
by this interaction. 
The binding interaction between recombinant soluble human ICOSL and 
recombinant hICOS.Fc was interrogated using two complimentary technology 
platforms, a surface based biosensor (Biacore) and a solution-based biosensor 
(KinExA).  Both platforms measure binding rates without the need for labeling the 
proteins.  SPR detection is based on the addition of mass to the sensor chip 
surface due to binding.  Binding of sICOSL to hICOS.Fc was detected as 
response in real time, allowing for direct measurement of binding rates (ka, kd) 
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and calculation of the binding affinity (KD). Based on the experimental design 
(Figure 5A), where bivalent hICOS.Fc was captured on the sensor chip surface 
at relatively low immobilization densities and based on the assumption that the 
expressed recombinant sICOSL that was injected over the surface was 
homogenous and monomeric, one would have expected that the kinetics of this 
interaction would have fit well to a 1:1 binding model.  The association and 
dissociation rates fit poorly to this model, however. Therefore the affinity of this 
interaction could not be accurately determined.   
There are several possibilities that could explain the poor fit of the data to 
the expected binding model.  Protein characterization using SEC-MALS revealed 
that the sICOSL was not solely monomeric, and that the protein had a tendency 
to dimerize in solution over time and with increasing temperatures.  Given the 
propensity of the molecule to dimerize in solution, it is possible if not likely that 
when two sICOSL molecules are brought into close proximity with one another by 
binding to separate arms of the bivalent hICOS.Fc molecule that increased 
dimerization may have occurred.  If this is the case then the rate of dissociation 
would no longer be driven by a single sICOSL molecule binding with a single 
binding site on hICOS.Fc.  It would instead be complicated by the strength of 
multiple binding interactions.  Since neither sICOSL nor hICOS.Fc is a true 
monomer, it was impossible to measure the intrinsic binding affinity of a 1:1 
interaction.   
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An advantage of the KinExA platform in comparison to SPR is that both 
molecules being studied can interact freely in solution. KinExA was used to 
measure the KD of the hICOSL: hICOS.Fc interaction when both molecules were 
in solution, or when hICOSL was expressed on the surface of CHO DR2 cells.  
The two different KinExA systems that were run showed similar KD values of 
approximately 190 pM when both molecules were in solution and approximately 
300 pM when hICOSL was on the surface of CHO DR2 cells.  For reasons 
described above, these KDs probably do not reflect a true 1:1 affinity value, but 
likely reflect the effect of avidity due to multiple binding partners interacting with 
different parts of the larger overall molecules to create a tighter overall 
interaction.   
Based on the fact that ICOS is known to exist on T cells as a disulfide-
linked dimer and that ICOSL has been shown to dimerize on the surface of 
APCs, the avidity that is measured by KinExA, may approximate a relevant 
functional affinity for this interaction in vivo.  It would be interesting to test this 
interaction on more biologically relevant cell systems.  Unfortunately due to the 
sensitivity limits of the KinExA instrument, it is not possible to measure the 
interaction with ICOS expressed on T cells or with ICOSL on APCs such as B 
cells or dendritic cells, due to the relatively low expression of ICOSL on the 
surface of these cells.  High-expressing cells at high concentrations, in large 
quantities, and often at high injection volumes are requirements for successfully 
measuring such an interaction using the KinExA platform.   
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The KD that was determined using KinExA was almost 1,000-fold tighter 
that the KD that was determined using SPR. Similar discrepancies between the 
binding affinity measured using SPR and the avidity measured using KinExA 
were observed in a study that looked at binding of various anti-TNF molecules to 
soluble TNF (sTNF), which is a costimulatory molecule that is found in solution 
as a trimer.  In this case, avidity measurements by KinExA are 10-20 fold 
stronger than affinity measurements by SPR (Kaymakcalan et al., 2009).  In both 
the case of sTNF and sICOSL, what may be happening is that as these 
costimulatory ligands bind to their receptors, the oligomerization states of the 
molecules allow for formation of multivalent immune complexes on the KinExA 
platform due to the freely interacting molecules in solution that are unable to form 
when a single molecule is captured at a low density on the SPR surface.  In 
Biacore experiments the maximum avidity effect that could be measured would 
most likely be due only to the interaction between two dimers, whereas on 
KinExA, the avidity effect could be due to the interaction with multivalent 
complexes of these molecules.  The dissociation of these larger complexes 
would be slower, due to multiple binding interactions that keep the overall 
complex associated, leading to a higher avidity.   
Thus, the binding affinity of monomeric ICOSL may not be the most 
relevant indicator of the true in vivo binding interaction between ICOS and ICOSL 
either in its shed form or on APCs.  All of this data suggests that the functional 
binding affinity for the ICOS: ICOSL interaction may be the accumulated strength 
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of multiple non-covalent binding interactions.  Results indicate that the functional 
binding affinity is significantly higher than the intrinsic affinity previously 
measured.  In lupus patients with higher levels of sICOSL in plasma signaling 
through ICOS: ICOSL is likely intensified due to the improper classification of 
self-antigens as foreign. In this case, it may be important to inhibit this interaction 
in order to reduce the inflammatory cascade initiated through this interaction that 
leads to the production of destructive autoantibodies. 
 
Future Directions 
As previously described, there is genetic, cellular, and proteomic evidence 
for the role of ICOS and ICOSL in SLE. Developing a better understanding of the 
role of reverse signaling caused by ICOS on T cells binding to ICOSL on APCs 
could lead to an improved understanding of the ideal approach for targeting this 
interaction therapeutically.  While some data suggests that reverse signaling 
occurs in mouse DCs via ICOS.Ig stimulation of ICOSL (Tang et al., 2009) there 
is not sufficient evidence that reverse signaling occurs via this interaction in 
humans.  Thus, additional research could extend the experiments performed in 
mouse DCs to human APCs, such as DCs or B cells, to confirm whether ICOS.Ig 
stimulation up- or down-regulates cytokine production in APCs.  Recombinant 
forms of ICOSL could be expressed on an APC cell line of the two different 
ICOSL splice variants (GL50 and B7-H2) to determine whether the 10 additional 
amino acids found in the more selectively expressed GL50 variant (found in 
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leukocytes, spleen, and lymph node tissue) are required in order to initiate this 
reverse signaling cascade vs. the ubiquitously expressed B7-H2 variant. 
The homologous molecule CTLA-4 has been shown to be effective 
therapeutically via its effects on both classical and reverse signaling pathways.  
As previously mentioned, CTLA-4 performs an inhibitory function on T cells by 
binding the CD28 ligands B7-1 and B7-2 with a higher affinity than CD28 (van 
der Merwe et al., 1997) thus inhibiting classical signaling through CD28 and 
activation of naïve T cells. Abatacept, or CTLA-4.Ig, is effective due to its 
inhibition of signaling through CD28.  A secondary effect was also discovered 
whereby abatacept initiates reverse signaling in APCs, inducing the transcription 
of IFN-γ, which activates IDO and thereby increases Trp catabolism, leading to 
decreased T cell proliferation (Grohmann et al., 2002).  This unintended 
secondary effect of abatacept fortunately also serves an immunosuppressive 
function. 
If inflammatory signaling is observed in APCs due to ICOS.Ig stimulation, 
then a preferred therapeutic approach may be the development of an antibody 
targeting either ICOS or ICOSL, which would not have the secondary effect of 
reverse signaling.  However, if the reverse signaling effect via ICOSL is found to 
be beneficial, one could envision an approach similar the CTLA-4.Ig therapeutic 
whereby ICOS.Ig is administered in order to initiate the reverse signaling 
cascade while simultaneously inhibiting the pro-inflammatory classical signaling 
cascade through ICOS on T cells.  The safety of such a molecule would need to 
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be thoroughly evaluated prior to administering this treatment in humans, however, 
as this would likely exacerbate inflammatory effects due to forward signaling 
mechanisms through ICOS on T cells. 
 ICOSL is the only B7 family member that is known to be shed and the 
protease responsible for the induction of shedding is unknown.  Logue et al. 
(2006) revealed that ICOSL is rapidly shed following ICOS binding and B cell 
receptor (BCR) engagement.  Using molecular biology techniques, the authors 
swapped out various domains of ICOSL with domains of the unsheddable 
costimulatory ligand B7-2.  They determined that shedding can be induced by 
phorbol-12-myristate-13-acetate (PMA) and by ICOS.  Treatment with the 
hydroxamate inhibitor, GM6001, a pan-metalloproteinase binder, completely 
inhibited shedding induced by PMA, but not shedding induced by ICOS.  The 
stalk region of ICOSL that connects the IgC domain to the transmembrane region 
was determined to be necessary for ectodomain shedding following PMA 
treatment.  In contrast, ICOS-induced shedding appears to involve the stalk and 
IgC domains of ICOSL.  The proteases responsible for both shedding 
mechanisms remain to be identified. 
It is unclear whether shed ICOSL exacerbates the autoimmune disease 
phenotype or serves a protective role.  Her et al.(2009) have shown that 
increased levels of soluble ICOSL are observed in human patients with active 
SLE compared to patients with inactive SLE, RA patients, and healthy controls.  
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This increase in shed ICOSL corresponds to a decrease in membrane-bound 
ICOSL on APCs, and no change in mRNA levels of ICOSL.  
Future experiments could be designed to specifically interrogate whether 
the shedding of ICOSL is a protective mechanism or a disease-exacerbating 
mechanism in SLE patients.  Existing evidence indicates that it may play a 
protective role by decreasing costimulatory signaling through ICOS and thus the 
production of downstream inflammatory cytokines; however that remains to be 
proven.  Based on evidence implicating both ICOS and ICOSL in SLE 
pathogenesis, both molecules may be interesting therapeutic targets for SLE 
treatment.  Acquiring a better understanding of whether shed ICOSL is protective 
or pathogenic could lead to a preferential targeting of one form of the protein.  
Work could also be performed to better understand the protease(s) responsible 
for the shedding of ICOSL.  Depending on the specificity of a given protease for 
ICOSL cleavage vs. other membrane proteins, design of an agonist or antagonist 
of that protease could also be considered as a therapeutic approach. 
Answering these fundamental biological questions could help to address 
the question of whether an inhibitor to ICOS or ICOSL could be a viable 
therapeutic for the treatment of SLE.  However, in vitro experiments and mouse 
models of SLE are inherently limited in their ability to model a very complex and 
heterogeneous human disease.  Thus, effectiveness in any preclinical system 
may help us to understand some of the nuances of the biology of this interaction, 
but are unlikely to lead to a true and complete understanding of the human 
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disease and aspects thereof.  Ultimately, the human experiment will need to be 
performed in order to truly answer this question.  However, understanding 
efficacy in SLE is not trivial.  Clinical trials must be carefully designed to account 
for the vast heterogeneity of the disease and to protect patients from its 
devastating effects, including organ damage.  This often involves enrolling 
patients who are already taking concomitant therapies and either tapering these 
therapies or establishing an effect of the experimental drug that is in addition to 
the background therapeutics of patients.  Treatment periods must typically be at 
least 6 months in order to observe symptomatic changes.   
A number of small and large molecules are currently being evaluated for 
the treatment of SLE.  B-cell-directed therapies target CD19, CD20, CD22, CD40 
and FcγRIIB.  These approaches generally attempt to deplete B cells or to inhibit 
their function.  T-cell-directed therapies do not aim for T cell depletion, but to 
promote T cell tolerance, block T cell activation and differentiation, and inhibit T 
cell trafficking. Targets for T-cell inhibition include CTLA-4, CD40L, and ICOSL. 
Cytokines are relevant in SLE due to their role in the generation and 
maintenance of inflammation. Cytokine-directed therapies including agents 
targeting B cell activating factor (BAFF), type I interferons, IL-6 or TNF are also 
being evaluated (Stohl, 2013).   
Monoclonal antibodies (mAbs) are being developed against ICOSL to 
inhibit the ICOS: ICOSL interaction.  The goal here is to inhibit the differentiation 
of activated T cells into differentiated TFH cells, which are important in the 
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maturation of B cells into antibody-producing cells in germinal centers.  Two 
Phase 1 clinical studies have been initiated using anti-ICOSL mAbs.  It will likely 
be several years before we learn whether these molecules are effective in the 
treatment of SLE (Stohl, 2013).   
Choosing the right groups of SLE patients may also be critical to running a 
successful clinical study.  For example, it would be difficult to remove background 
medications from patients with the most severe forms of SLE due to safety risks.  
However, it may be difficult to observe a measurable effect in those patients with 
the mildest form of the disease.  Therefore, patients who have moderate SLE 
may be good candidates for a clinical trial that attempts to taper and/or remove 
background medications in order to most clearly observe the effect of the study 
drug. 
It will also be important to evaluate a number of systemic biomarkers in 
addition to the clinical endpoints such as SLEDAI, BILAG, or SRI.  Meaningful 
biomarkers for a therapy targeting ICOSL would likely be T cells and B cells, 
which can be measured by flow cytometry.  Safety biomarkers such as neutrophil 
levels and viral load levels should also be evaluated in order to determine safety 
risks prior to occurrence of adverse safety-related events due to too much 
immune suppression.  It would be useful to attempt to stratify subgroups of 
patients within a clinical study by measuring biomarkers such as autoantibody 
reactivities and levels prior to enrollment and at several time points during the 
course of treatment in order to determine if further stratification is needed.  
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Finally it would be useful to measure genes and proteins that are indicative of the 
overall level of inflammation such as interferon-modulated genes and proteins 
and measurable pro- and anti-inflammatory cytokines and chemokines.  In 
particular, levels of soluble ICOSL in patients’ serum could be measured at 
baseline as a potential patient stratification marker to determine whether patients 
with higher levels of sICOSL respond more or less favorably to therapy.  sICOSL 
could also be measured longitudinally to determine whether levels increased or 
decreased due to treatment and/or a reduction in SLE disease activity. 
Due to the heterogeneity of SLE, it is unlikely that any one therapeutic 
approach that is pursued will provide an optimal and effective treatment for all 
SLE patients.  It is more likely that subsets of patients with common molecular 
and clinical phenotypes will benefit from different subsets and/or combinations of 
these therapies.  Among the major challenges that remain will be to properly 
design ongoing and future clinical studies in order to target the subsets of 
patients that will most benefit from a given therapy and choosing meaningful and 
attainable trial endpoints in order to differentiate therapies with the potential to 
ameliorate this devastating disease from those that are ineffective.  
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APPENDIX 
 
Amino Acid Symbols 
Full Name 
3-Letter 
Symbol 
1-Letter 
Symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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